IMPEDIMED LIMITED — Capital/Financing Update 2015

Oct 25, 2015

==> picture [103 x 95] intentionally omitted <==

----- Start of picture text ----- ASX: IPD----- End of picture text -----

26 October 2015

ASX ANNOUNCEMENT

ImpediMed Announces Purchase of Key Assets and Intellectual Property

– “ ” Brisbane, Australia ImpediMed Limited (ASX: IPD) ( The Company ), a leading provider of technology to measure, monitor and manage fluid status and body composition, today announced that it has acquired certain key assets and intellectual property from Intersection Medical Incorporated. The purchase includes all rights, title, and interest in bioimpedance spectroscopy and other associated technology related to the field of chronic heart failure. The terms of the purchase agreement are confidential.

“This asset purchase further enhances ImpediMed’s intellectual property portfolio and will aid in our strategy to expand into other indications,” said Richard Carreon, Managing Director and CEO. “The need to accurately measure and monitor fluid levels is critical in the clinical assessment and management of chronic heart failure patients and we believe we have a simple, sophisticated platform technology which may accomplish this”.

ImpediMed is the world’s leading developer of technology utilising bioimpedance spectroscopy to precisely measure fluid status and aid in the clinical assessment of fluid burden. The company currently offers its L-Dex product to aid in the clinical assessment of unilateral lymphoedema of the extremities in cancer patients and is preparing for the full US launch of L-Dex, commencing this calendar year.

– ENDS –

Richard Carreon Managing Director & CEO

For further information contact: Richard Carreon, ImpediMed Managing Director & CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

Kyahn Williamson, Buchan Investor and Media Relations T: +61 3 9866 4722 E: kwilliamson@buchanwe.com.au

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

Page 1 of 2

For more information, visit: www.impedimed.com.au

Page 2 of 2